Dr. Adrian J. Carter
Boehringer Ingelheim Pharma GmbH
Dr. Adrian Carter, is Corporate Vice President and Global Head of Discovery Research Coordination at Boehringer Ingelheim where he is currently responsible for guiding research policy, managing strategic and operational initiatives across all research sites, and overseeing competitive intelligence activities in R&D. He originally graduated from the University of Wales in Cardiff with an honours degree in biology, has a Ph.D. in pharmacology from the Department of Medicine at the University of Nottingham, and an executive MBA from the University of Mainz. His career at Boehringer Ingelheim spans more than 31 years including 8 years as head of neuropharmacology and 10 years in business development. He has been in his current role in discovery research since 2011. Dr. Adrian Carter currently represents Boehringer Ingelheim on the board of trustees for the Structural Genomics Consortium (SGC) and the Naturwissenschaftliches und Medizinisches Institut (NMI) in Reutlingen as well as the Innovative Medicines Strategy (InnoMedS) Priority Working Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is also a member of the steering committee for BioFIT, a leading partnering event in Europe for open innovation, technology transfer and collaborative research in the field of life sciences, a member of the board of the Biotech Cluster Rhine-Neckar (BioRN), an association that promotes the development of the biotech region into one of the leading life-science clusters in Europe, as well as a member of the Health Axis Europe (HAE) executive board, an alliance of European health technology clusters in Cambridge (UK), Leuven (Belgium), Heidelberg (Germany), Maastricht (Netherlands) and Copenhagen (Denmark).
Check out Adrian’s scientific contributions at https://www.researchgate.net/profile/Adrian_Carter2
At "Future Medicine" he will talk about "Harnessing the Creative Power of the Scientific Crowd".